2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1715

Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 24 Month Open Label, Extension Phase
Abstract Number: 873

Imbalance Between Histone Acetyl Transferase and Histone Deacteylase Activities and Modulation of HDAC Activity and Tnfa Production by HDAC Inhibitors in Patients with Ankylosing Spondylitis or Rheumatoid Arthritis
Abstract Number: 418

Immediate Early Response Gene X-1 Is Over-Expressed and Regulates Apoptosis and Cytokine Production in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 1808

Immune Activating Effects of Co-Stimulation of TLR Agonists and Cytokines On Primary and Immortalized Keratinocytes From a Patient with a CARD14 Mediated Pustular Psoriasis (CAMPS) and Healthy Controls
Abstract Number: 672

Immune Complexes and Autoantibodies to Oxidized Lipids in Systemic Lupus Erythematosus
Abstract Number: 322

Immune Response to Porphyromonas Gingivalis Citrullinated α-Enolase Cross-Reacts with Human α-Enolase in Polyarticular JIA Patients
Abstract Number: 1954

Immune Responses to NXP-2 and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients
Abstract Number: 1999

Immunogenicity and Safety of Two Doses of Influenza A H1N1⁄2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old
Abstract Number: 485

Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Abstract Number: 2521

Immunoglobulin G Fc Receptor Activity in Vivo Is Under Complement Control
Abstract Number: 475

Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Abstract Number: 1888

Immunology for Rheumatology Residents: Working towards a National Curriculum Consensus
Abstract Number: 323

Immunoprecipitation and Advanced Proteomics for the Discovery of Novel Antigenic Targets in Juvenile Idiopathic Arthritis
Abstract Number: 1102

Immunoreactive Collagen Type II Cleavage Products and Their Nitrated Forms in Rheumatoid Arthritis and Osteoarthritis: An Outpatient Cross-Sectional Study
Abstract Number: 1892

Impact of a Lupus Patient Education Event On Knowledge about Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].